Florian Kahles

Florian Kahles

Auto-generated profile, based on publicly available information

Florian Kahles

Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen , Pauwelsstraße 30, 52074 Aachen, Germany

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2025 in European Heart Journal
Verified
Journal Article
Open access
BKBerkan Kurt
Berkan Kurt
MRMartin Reugels
Martin Reugels
KSKai Markus Schneider
Kai Markus Schneider
JSJens Spiesshoefer
Jens Spiesshoefer
AMAndrea Milzi
Andrea Milzi
FKFlorian Kahles
Florian Kahles
Background and Aims: High-sensitivity C-reactive protein (hsCRP) is a marker of inflammation and predicts cardiovascular (CV) risk in individuals without known atherosclerotic CV disease (ASCVD). More information about its clinical relevance will help evaluate the general utility of hsCRP as a routine clinical biomarker to identify patients at residual risk. Methods: In this population-based study, hsCRP was measured in 448 653 UK Biobank participants without known ASCVD. The association of hsCRP with major adverse cardiovascular events (MACE), CV death and all-cause death was assessed using Cox proportional hazards models. Results: The cohort had a median age of 57 years, 55.4% were female, and median hsCRP levels were 1.32 mg/L. A repeat hsCRP measurement in 15 967 participants after 4.4 years showed long-term stability. In covariate-adjusted models individuals with hsCRP levels >3 mg/L had a 34% higher risk of MACE, a 61% and 54% increased risk of CV death and all-cause death compared to those with hsCRP <1 mg/L. Subjects with hsCRP levels ≥2 mg/L vs <2 mg/L had a 22% increased risk of MACE, and a 37% and 34% higher risk of CV death and all-cause death. The association of hsCRP with all endpoints was consistent across subgroups. Predictive performance of hsCRP ranked above conventional risk factors. Integration of hsCRP improved SCORE2 and provided a total net reclassification improvement of 14.1% for prediction of MACE. Conclusions: These data confirm hsCRP as a clinically relevant predictor of CV events in individuals without known ASCVD and support its assessment in primary prevention.

3 February 2016 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
CLCorinna Lebherz
Corinna Lebherz
FKFlorian Kahles
Florian Kahles
KPKatja Piotrowski
Katja Piotrowski
MVMichael Vogeser
Michael Vogeser
AFAnn Christina Foldenauer
Ann Christina Foldenauer
MLMichael Lehrke
Michael Lehrke
Glucagon-like peptide-1 (GLP-1) is an incretin hormone, which gets secreted in response to nutritional stimuli from the gut mediating glucose-dependent insulin secretion. Interestingly, GLP-1 was recently found to be also increased in response to inflammatory stimuli in an interleukin 6 (IL-6) dependent manner in mice. The relevance of this finding to humans is unknown but has been suggested by the presence of high circulating GLP-1 levels in critically ill patients that correlated with markers of inflammation. This study was performed to elucidate, whether a direct link exists between inflammation and GLP-1 secretion in humans. We enrolled 22 non-diabetic patients scheduled for cardiac surgery as a reproducible inflammatory stimulus with repeated blood sampling before and after surgery. Mean total circulating GLP-1 levels significantly increased in response to surgery from 25.5 ± 15.6 pM to 51.9 ± 42.7 pM which was not found in a control population. This was preceded by an early rise of IL6, which was significantly associated with GLP-1 under inflammatory but not basal conditions. Using repeated measure ANCOVA, IL6 best predicted the observed kinetics of GLP-1, followed by blood glucose concentrations and cortisol plasma levels. Furthermore, GLP-1 plasma concentrations significantly predicted endogenous insulin production as assessed by C-peptide concentrations over time, while an inverse association was found for insulin infusion rate. We found GLP-1 secretion to be increased in response to inflammatory stimuli in humans, which was associated to parameters of glucose metabolism and best predicted by IL6.

6 November 2025 in Current Heart Failure Reports
Verified
Journal Article
Open access
PDF file
BKBerkan Kurt
Berkan Kurt
KRKonstantin Rex
Konstantin Rex
MRMartin Reugels
Martin Reugels
CFChristopher B. Fordyce
Christopher B. Fordyce
MFMarat Fudim
Marat Fudim
FKFlorian Kahles
Florian Kahles
Purpose of Review: Heart failure (HF) remains a leading cause of morbidity and mortality worldwide. Increasing evidence highlights that systemic low-grade inflammation is a key pathophysiological driver of HF. This review seeks to examine the diagnostic and therapeutic relevance of inflammatory biomarkers – specifically interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hsCRP) – and evaluate their potential for improving risk stratification and enabling personalized treatment approaches in HF. Recent Findings: IL-6 and hsCRP have emerged as important markers of residual inflammatory risk in HF. Elevated levels of these biomarkers are associated with increased risk of incident HF and adverse outcomes in established disease. While hsCRP is as a downstream marker of inflammation with no causal involvement, Mendelian randomization studies support a causal role of IL-6 signaling in the development of HF and coronary artery disease. Recent and ongoing clinical trials support the concept of targeting inflammatory pathways as a therapeutic strategy in selected HF populations. Summary: Inflammatory biomarkers, particularly IL-6 and hsCRP, are promising tools for advancing precision medicine in HF by improving individual risk assessment and guiding anti-inflammatory interventions. Further large-scale studies are needed to validate the integration of inflammatory biomarkers into clinical algorithms for HF and explore their potential role in future guideline recommendations and personalized prevention strategies.

30 August 2025 in European Heart Journal
Verified
Journal Article
Open access
FWFlorian A Wenzl
Florian A Wenzl
PWPeizhi Wang
Peizhi Wang
FKFlorian Kahles
Florian Kahles
KBKatharina Beck
Katharina Beck
EGEvangelos Giannitsis
Evangelos Giannitsis
TLThomas F. Lüscher
Thomas F. Lüscher
Background and Aims: The gut microbiota is a modulator of cardiometabolic disease. Circulating imidazole propionate (ImP) is a microbiota-derived proatherogenic amino acid metabolite modulating the inflammatory response of myeloid cells, endothelial function and glucose metabolism. This study examined the prognostic value of ImP in patients with coronary artery disease (CAD). Methods: Circulating ImP levels were measured in independent prospective cohorts of patients with acute coronary syndrome (ACS, Switzerland n=4937, Germany n=1497) and chronic coronary syndrome (CCS, Germany n=701). Major adverse cardiovascular events (MACE), defined as the first occurrence of a composite of death, nonfatal myocardial infarction, or nonfatal stroke after admission, were the primary endpoint. Cox models, accounting for established risk factors including the gut-derived cardiovascular risk factor trimethylamine N-oxide (TMAO), were used to evaluate the predictive value of ImP. Results: Circulating ImP was associated with more advanced CAD and with cardiometabolic characteristics including diabetes and elevated high-sensitivity C-reactive protein. High ImP was an independent predictor of MACE (Swiss ACS cohort: hazard ratio [HR] per log2 increase 1.22, 95% confidence interval [CI] 1.10–1.35, P<0.001; German ACS cohort: HR 2.34, 95% CI 1.46–3.76, P<0.001; German CCS cohort: HR 1.32, 95% CI 1.13–1.53, P<0.001) and of mortality (Swiss ACS cohort: HR 1.34, 95% CI 1.17–1.54, P<0.001; German ACS cohort: HR 2.38, 95% CI 1.48–3.82, P<0.001; German CCS cohort: HR 1.50, 95% CI 1.14–1.98, P=0.004) after adjustment for established risk factors. ImP provided predictive value beyond TMAO (Swiss ACS cohort: HR 1.30, 95% CI 1.05–1.61, P=0.014; German CCS cohort: HR 1.31, 95% CI 1.11–1.53, P=0.001). Conclusions: Gut microbiota-derived ImP predicted MACE in patients with CAD independently of traditional risk factors and holds promise as a therapeutic target. ImP may refine risk stratification for personalised secondary prevention strategies.

1 June 2026 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
LQLuis Quintana
Luis Quintana
NTNadim Tabaza
Nadim Tabaza
BKBerkan Kurt
Berkan Kurt
FKFlorian Kahles
Florian Kahles
Glucagon-like peptide-1 receptor agonists (GLP-1RA) are established treatment options for type 2 diabetes and obesity. This class of medications has redefined care by lowering glucose, reducing body weight, and improving cardiovascular outcomes. Beyond metabolic benefits, accumulating evidence indicates that GLP-1RA exert direct anti-inflammatory effects across multiple organ systems. Chronic inflammation is a driving force behind many prevalent diseases, including diabetes, cardiovascular disease, neurodegenerative disorders, and inflammatory bowel disease. This review summarizes the current evidence of the anti-inflammatory effects of GLP-1RA, highlighting data from preclinical models and clinical trials across different diseases. By targeting both metabolic and inflammatory pathways, GLP-1RA may offer dual cardiometabolic and immunomodulatory protection, positioning these agents as promising candidates for broader therapeutic applications. However, several key questions remain regarding causality, the precise molecular mechanisms involved, and the extent to which these anti-inflammatory effects can be translated into effective therapies for nonmetabolic inflammatory diseases.

3 February 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
PKPaul Kiessling
Paul Kiessling
MJMehdi Joodaki
Mehdi Joodaki
DPDaryna Pikulska
Daryna Pikulska
ESEmilia Scheidereit
Emilia Scheidereit
GCGiulia Cesaro
Giulia Cesaro
CKChristoph Kuppe
Christoph Kuppe
The adult mammalian heart has a limited regenerative capacity. Following injury, cardiomyocytes undergo a hypertrophic response accompanied by polyploidization, which has been described as a barrier to proliferation and regeneration of the heart 1,2 . However, the unique molecular programs of polyploidy, or genome multiplied cardiomyocytes, and their influence on the disease-related myocardial remodelling process remains unclear. Here, we integrate single-nuclei and high-resolution spatial multi-omics across human, rat, and mouse hearts to define novel cardiac cell states and their tissue niches in ischemic and non-ischemic heart disease. Computational analysis across scales allowed us to generate detailed networks of the cardiac tissue remodelling process as well as tissue and sub-cellular environments uniquely enriched in polyploid cardiomyocytes or their diploid origins. We identify a conserved, dichotomous transcriptional program distinguishing diploid from polyploid cardiomyocytes. Polyploid cardiomyocytes demonstrated rewired metabolic and chromatin-remodeling transcriptional programs and recapitulate the gene signature of immature human fetal cardiomyocytes. Notably, we observe that polyploid cardiomyocytes—rather than the general myocyte population—are the primary sites of enrichment for major heart-failure drug targets, including the mineralocorticoid, β1-adrenergic, and glucagon-like peptide-1 receptors. Based on our cross-species dataset we further identified TNIK, a Wnt-pathway regulator expressed in polyploid cardiomyocytes across species, as a potential therapeutic target and demonstrate that pharmacological TNIK inhibition improves cardiac function after myocardial infarction in rats. Together, this species-spanning, disease-resolved study redefines cardiomyocyte heterogeneity in heart disease and suggests a therapeutic path to heart failure treatment by targeting polyploid cardiomyocytes.